by Yeon Hee Park, Tae-Yong Kim, Gun Min Kim, Seok Yun Kang,
In Hae Park, Jee Hyun Kim, Kyoung Eun Lee, Hee Kyung Ahn, Moon Hee Lee, Hee-Jun
Kim, Han Jo Kim, Jong In Lee, Su-Jin Koh, Ji-Yeon Kim, Kyung-Hun Lee, Joohyuk
Sohn, Sung-Bae Kim, Jin-Seok Ahn, Young-Hyuck Im, Kyung Hae Jung, Seock-Ah Im,
Korean Cancer Study Group (KCSG)
The Lancet Oncology: ARTICLES| VOLUME
20, ISSUE 12, P1750-1759, DECEMBER 01, 2019
Exemestane plus palbociclib with ovarian function
suppression showed clinical benefit compared with capecitabine in terms of
improved progression-free survival in premenopausal patients with hormone
receptor-positive, HER2-negative metastatic breast cancer. Palbociclib plus
exemestane with ovarian suppression is an active treatment option in
premenopausal patients with hormone receptor-positive, HER2-negative metastatic
breast cancer who have been pretreated with tamoxifen.
